Challenging BRAF/EGFR co-inhibition in NSCLC using sequential liquid biopsies
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference10 articles.
1. High-throughput detection of clinically targetable alterations using next-generation sequencing;Vendrell;Oncotarget,2017
2. Role of circulating-tumor DNA analysis in non-small cell lung cancer;Jiang;Lung Cancer,2015
3. Durable response to combination of dabrafenib and trametinib in BRAF V600E-mutated non-small-cell lung cancer;Pervere;Clin. Lung Cancer,2017
4. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial;Planchard;Lancet Oncol.,2017
5. Phase I/II trial of labetuzumab govitecan (anti-CEACAM5/SN-38 antibody-drug conjugate) in patients with refractory or relapsing metastatic colorectal cancer;Dotan;J. Clin. Oncol.,2017
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Pathways and targeting avenues of BRAF in non-small cell lung cancer;Expert Opinion on Therapeutic Targets;2024-07-02
2. Liquid biopsy for the management of NSCLC patients under osimertinib treatment;Critical Reviews in Clinical Laboratory Sciences;2024-02-02
3. Promising response of dabrafenib, trametinib, and osimertinib combination therapy for concomitant BRAF and EGFR-TKI resistance mutations;Anti-Cancer Drugs;2023-08-15
4. Acquired resistance mechanisms to osimertinib: The constant battle;Cancer Treatment Reviews;2023-05
5. Targeting Oncogenic Driver Mutations in Lung Cancer;El in Molecular Onco;2023-01-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3